Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Entertainment Now
Spring Wellness
Home & Garden
Home Improvement
Home & Realty
Outdoor Guide
Women
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
Readersâ Choice
Auction
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Caribou Biosciences, Inc.
Caribou Biosciences to Participate in Upcoming Investor Conferences
May 31, 2023
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
May 08, 2023
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
May 01, 2023
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
April 17, 2023
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
April 04, 2023
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
March 29, 2023
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients
March 29, 2023
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 09, 2023
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 08, 2023
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
February 01, 2023
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
December 12, 2022
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy
December 12, 2022
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
November 29, 2022
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
November 21, 2022
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 08, 2022
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
November 07, 2022
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting
November 03, 2022
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022
October 18, 2022
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Tickers
CRBU
Caribou Biosciences Announces Closing of Upsized Initial Public Offering
July 27, 2021
From
Caribou Biosciences, Inc.
Via
Business Wire
Tickers
CRBU
Caribou Biosciences Announces Pricing of Upsized Initial Public Offering
July 22, 2021
From
Caribou Biosciences, Inc.
Via
Business Wire
Tickers
CRBU
Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
July 12, 2021
From
Caribou Biosciences, Inc.
Via
Business Wire
Caribou Biosciences Appoints Scott Braunstein, M.D. to Board of Directors
June 22, 2021
From
Caribou Biosciences, Inc.
Via
Business Wire
Caribou Biosciences Announces Appointment of Katy Rezvani, M.D., Ph.D. and Christopher Sturgeon, Ph.D. to its Scientific Advisory Board
May 17, 2021
From
Caribou Biosciences, Inc.
Via
Business Wire
Caribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors
May 05, 2021
From
Caribou Biosciences, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.